News
IMUX
--
0.00%
--
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific,...
PR Newswire · 1h ago
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the ...
PR Newswire · 03/31 13:50
Immunic And 4SC AG Sign Agreement Under Which Immunic Will Settle Its Remaining Obligation Of A 4.4% Royalty On Net Sales Of IMU-838 For $17.25M In 50% Cash And 50% Stock
Immunic, Inc. (NASDAQ:IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime
Benzinga · 03/31 12:52
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
Immunic Inc’s (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst: Gobind Singh initiated coverage of Immunic with a Mar...
Benzinga · 03/24 17:26
Immunic initiated at JMP citing potential of multiple sclerosis candidate
Immunic ([[IMTX]]) is on the rise today after JMP Securities initiated its coverage with a market outperform rating as analyst Gobind Singh points to the potential of the company’s lead
Seekingalpha · 03/24 13:34
DJ Immunic Initiated at Market Outperform by JMP Securities
Dow Jones · 03/24 11:25
DJ Immunic Price Target Announced at $55.00/Share by JMP Securities
Dow Jones · 03/24 11:25
Should You Take Comfort From Insider Transactions At Immunic, Inc. (NASDAQ:IMUX)?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Simply Wall St. · 03/19 09:20
Immunic, Inc. to Participate in Industry and Investor Conferences in March
PR Newswire · 03/02 11:30
Wedbush Sticks to Its Buy Rating for Immunic (IMUX)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic (IMUX) yesterday and set a price target of $72.00. The company's shares closed last
SmarterAnalyst · 03/02 01:05
10-K: IMMUNIC, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 02/26 12:22
Immunic EPS beats by $0.05
Immunic (IMUX): FY GAAP EPS of -$2.81 beats by $0.05.Cash and Cash Equivalents of $127.5MPress Release
Seekingalpha · 02/26 11:46
Immunic FY Loss/Shr $2.81 >IMUX
Immunic FY Loss/Shr $2.81 >IMUX
Dow Jones · 02/26 11:33
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
, /PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results for the year ended and highlighted...
PR Newswire - PRF · 02/26 11:30
Press Release: Immunic, Inc. Reports Year End -2-
Dow Jones · 02/26 11:30
Wedbush Reaffirms Their Buy Rating on Immunic (IMUX)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic (IMUX) yesterday and set a price target of $72.00. The company's shares closed last
SmarterAnalyst · 02/22 01:05
PETS, IMUX, EVGN and OTIC among after-hours movers
Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%.
Seekingalpha · 02/19 22:46
Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study
Benzinga · 02/18 13:26
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
BRIEF-Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-Of-Concept Clinical Trial
reuters.com · 02/18 12:28
Webull provides a variety of real-time IMUX stock news. You can receive the latest news about Immunic Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.